Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 6/20 | 0.49 |
| ▸ | HTR2C | P28335 | 2/20 | 0.49 |
| ▸ | HTR2B | P41595 | 2/20 | 0.49 |
| ▸ | HTR1A | P08908 | 2/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.46 |
| ▸ | PRKX | P51817 | 1/20 | 0.46 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.46 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.46 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15650257 | 0.95 | CHRNB2 (0.55) | CHRNB2CHRNA4ROCK1HTR2CHTR2B | |
| SCHEMBL19582779 | 0.95 | CHRNB2 (0.55) | CHRNB2CHRNA4ROCK1HTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL15649585 | 0.93 | CHRNB2 (0.54) | CHRNB2CHRNA4ROCK1HTR2CHTR2B | |
| SCHEMBL4700578 | 0.88 | HTR2C (0.59) | CHRNB2CHRNA4ROCK1HTR2CHTR2B | |
| SCHEMBL4125994 | 0.88 | HTR2C (0.59) | CHRNB2CHRNA4ROCK1HTR2CHTR2B | |
| SCHEMBL3380245 | 0.88 | HTR2C (0.59) | CHRNB2CHRNA4ROCK1HTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL28313668 | 0.86 | HTR2C (0.58) | CHRNB2CHRNA4ROCK1HTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL28313667 | 0.86 | HTR2C (0.58) | CHRNB2CHRNA4ROCK1HTR2CHTR2B | |
| SCHEMBL19599782 | 0.83 | CHRNB2 (0.60) | CHRNB2CHRNA4ROCK1HTR1ASLC6A2 | |
| SCHEMBL16242402 | 0.82 | EPHX2 (0.58) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3191453-B1 | PHENYL-(AZA)CYCLOALKYL CARBOXYLIC ACID GPR120 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2019-10-23 | — | — | EP | disclosed |
| EP-3191453-B1 | PHENYL-(AZA)CYCLOALKYL CARBOXYLIC ACID GPR120 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2019-10-23 | — | — | EP | disclosed |
| US-10336684-B2 | Phenyl-(aza)cycloalkyl carboxylic acid GPR120 modulators | BRISTOL=MYERS SQUIBB COMPANY (US) | 2019-07-02 | — | — | US | disclosed |
| US-10336684-B2 | Phenyl-(aza)cycloalkyl carboxylic acid GPR120 modulators | BRISTOL=MYERS SQUIBB COMPANY (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180319737-A1 | PHENYL-(AZA)CYCLOALKYL CARBOXYLIC ACID GPR120 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-11-08 | — | — | US | disclosed |
| US-20170327457-A1 | PHENYL-(AZA)CYCLOALKYL CARBOXYLIC ACID GPR120 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-16 | — | — | US | disclosed |
| US-20170327457-A1 | PHENYL-(AZA)CYCLOALKYL CARBOXYLIC ACID GPR120 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-16 | — | — | US | disclosed |
| US-20170327457-A1 | PHENYL-(AZA)CYCLOALKYL CARBOXYLIC ACID GPR120 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-16 | — | — | US | disclosed |
| EP-3191453-A1 | PHENYL-(AZA)CYCLOALKYL CARBOXYLIC ACID GPR120 MODULATORS | Bristol-Myers Squibb Company (US) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016040225-A1 | PHENYL-(AZA)CYCLOALKYL CARBOXYLIC ACID GPR120 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170327457-A1 | PHENYL-(AZA)CYCLOALKYL CARBOXYLIC ACID GPR120 MODULATORS | GPR88, GPR55, GPR180 | CHRNB2 445/4885CHRNA4 354/4885ROCK1 2818/4885 |
| US-20180319737-A1 | PHENYL-(AZA)CYCLOALKYL CARBOXYLIC ACID GPR120 MODULATORS | GPR88, GPR55, GPR180 | CHRNB2 445/4885CHRNA4 354/4885ROCK1 2818/4885 |
| US-10336684-B2 | Phenyl-(aza)cycloalkyl carboxylic acid GPR120 modulators | GPR88, GPR55, GPR180 | CHRNB2 445/4885CHRNA4 354/4885ROCK1 2818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.